BioRestorative Therapies, Inc. (NASDAQ:BRTX) said Tuesday that Australia’s intellectual property authority has approved a key patent application covering its ThermoStem® technology, expanding global protection for the company’s stem cell–based treatment approach targeting obesity and metabolic disorders.
The allowance, granted by IP Australia under Patent Application No. 2020265664, relates to “Non-naturally occurring three-dimensional (3D) brown adipose-derived stem cell aggregates, and methods of generating and using the same.” The patent provides broad protection for BioRestorative’s allogeneic, off-the-shelf brown adipose-derived stem cell (BADSC) platform, including methods for producing non-naturally occurring three-dimensional stem cell aggregates.
The company said the development strengthens intellectual property coverage for ThermoStem®, which is being advanced as a potential next-generation, cell-based alternative to GLP-1 therapies — one of the fastest-expanding segments in the global pharmaceutical market.
BioRestorative believes its approach could offer longer-lasting therapeutic effects while improving safety and dosing flexibility compared with existing GLP-1 drugs.
“As we continue our mission to advance cell-based therapeutic candidates that may offer the potential for longer-lasting efficacy with improved safety and dosing advantages over GLP-1 drugs, we remain focused on building our global patent protection to strengthen our competitive moat in obesity and related metabolic diseases, and on bolstering our position as a leader in the stem cell-based therapies and products space,” said Lance Alstodt, BioRestorative’s Chief Executive Officer. “I am proud of our team’s diligent work in securing patent protection across key markets, and adding this Australian patent application to our growing global IP portfolio underscores our commitment and belief in the incredible potential of ThermoStem®.”
The newly allowed patent adds to BioRestorative’s expanding international intellectual property portfolio as the company continues clinical development of regenerative medicine therapies.
About BioRestorative Therapies, Inc.
BioRestorative Therapies develops therapeutic products based on cell and tissue engineering protocols, primarily using adult stem cells. Its core clinical programs focus on treatments for spinal and disc disease as well as metabolic disorders, alongside a commercial BioCosmeceutical platform.